TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback